Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.

Kantrowitz J, Citrome L, Javitt D.

CNS Drugs. 2009 Aug;23(8):681-91. doi: 10.2165/00023210-200923080-00005. Review.

2.

Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.

Göder R, Fritzer G, Gottwald B, Lippmann B, Seeck-Hirschner M, Serafin I, Aldenhoff JB.

Pharmacopsychiatry. 2008 May;41(3):92-9. doi: 10.1055/s-2007-1004592.

PMID:
18484550
3.

mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia.

Wierońska JM, Kłeczek N, Woźniak M, Gruca P, Łasoń-Tyburkiewicz M, Papp M, Brański P, Burnat G, Pilc A.

Neurochem Int. 2015 Sep;88:97-109. doi: 10.1016/j.neuint.2015.03.010. Epub 2015 Apr 8.

PMID:
25863284
4.

Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use.

Baandrup L, Glenthøj BY, Jennum PJ.

Psychiatry Res. 2016 Jun 30;240:163-169. doi: 10.1016/j.psychres.2016.04.031. Epub 2016 Apr 15.

PMID:
27107670
5.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
6.

Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.

Kluge M, Schacht A, Himmerich H, Rummel-Kluge C, Wehmeier PM, Dalal M, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T, Schuld A.

Schizophr Res. 2014 Jan;152(1):255-60. doi: 10.1016/j.schres.2013.11.009. Epub 2013 Dec 5.

PMID:
24315135
7.

Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.

Huang YS, Guilleminault C.

Pediatr Neurol. 2009 Jul;41(1):9-16. doi: 10.1016/j.pediatrneurol.2009.02.008.

PMID:
19520267
8.

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases.

Trotti LM, Karroum EG.

Curr Neurol Neurosci Rep. 2016 Jul;16(7):63. doi: 10.1007/s11910-016-0664-3. Review.

PMID:
27180068
9.

Sleep in schizophrenia: impairments, correlates, and treatment.

Benson KL.

Psychiatr Clin North Am. 2006 Dec;29(4):1033-45; abstract ix-x. Review.

PMID:
17118280
10.

The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia.

Liu SK, Fitzgerald PB, Daigle M, Chen R, Daskalakis ZJ.

Biol Psychiatry. 2009 Mar 15;65(6):503-9. doi: 10.1016/j.biopsych.2008.09.012. Epub 2008 Oct 31.

PMID:
18950746
11.

EEG biomarkers of target engagement, therapeutic effect, and disease process.

Featherstone RE, McMullen MF, Ward KR, Bang J, Xiao J, Siegel SJ.

Ann N Y Acad Sci. 2015 May;1344:12-26. doi: 10.1111/nyas.12745. Epub 2015 Mar 30.

PMID:
25823856
12.

Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.

Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D.

Am J Psychiatry. 2008 Dec;165(12):1585-93. doi: 10.1176/appi.ajp.2008.08030395. Epub 2008 Oct 15. Erratum in: Am J Psychiatry. 2009 Jan;166(1):120.

13.

The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.

Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A.

Br J Pharmacol. 2011 Jul;163(5):1034-47. doi: 10.1111/j.1476-5381.2011.01301.x.

14.

Treatment options for residual insomnia in schizophrenia.

Baandrup L, Jennum P, Lublin H, Glenthoj B.

Acta Psychiatr Scand. 2013 Jan;127(1):81-2. doi: 10.1111/acps.12016. Epub 2012 Oct 26. Review. No abstract available.

PMID:
23106614
15.

Critical review of GABA-ergic drugs in the treatment of schizophrenia.

Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ 3rd, Rose RM.

J Clin Psychopharmacol. 1999 Jun;19(3):222-32. Review.

PMID:
10350028
16.

Main neuroendocrine features and therapy in primary sleep troubles.

Amihăesei IC, Mungiu OC.

Rev Med Chir Soc Med Nat Iasi. 2012 Jul-Sep;116(3):862-6.

PMID:
23272543
17.

Pharmacological strategies for enhancing cognition in schizophrenia.

Barch DM.

Curr Top Behav Neurosci. 2010;4:43-96. Review.

PMID:
21312397
18.

Differential effects of sodium oxybate and baclofen on EEG, sleep, neurobehavioral performance, and memory.

Vienne J, Lecciso G, Constantinescu I, Schwartz S, Franken P, Heinzer R, Tafti M.

Sleep. 2012 Aug 1;35(8):1071-83. doi: 10.5665/sleep.1992.

19.

Sleep Disturbances in Schizophrenia.

Kamath J, Virdi S, Winokur A.

Psychiatr Clin North Am. 2015 Dec;38(4):777-92. doi: 10.1016/j.psc.2015.07.007. Epub 2015 Aug 22. Review.

PMID:
26600108
20.

Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.

Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC.

J Clin Psychiatry. 2009 Dec;70(12):1674-80. doi: 10.4088/JCP.08m04683. Epub 2009 Aug 11.

Supplemental Content

Support Center